Fabien Zoulim Selected Research

Glycoside Hydrolase Inhibitors

4/2007	Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
4/2006	Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabien Zoulim Research Topics

Disease

135	Infections 05/2024 - 01/2002
114	Chronic Hepatitis B 05/2024 - 01/2002
53	Hepatitis B 04/2024 - 01/2002
52	Fibrosis (Cirrhosis) 08/2023 - 08/2005
28	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 08/2005
23	Liver Diseases (Liver Disease) 01/2023 - 01/2002
19	Chronic Hepatitis C 06/2022 - 09/2004
15	Hepatitis 09/2023 - 10/2004
13	Liver Cirrhosis (Hepatic Cirrhosis) 08/2023 - 11/2004
13	Neoplasms (Cancer) 01/2023 - 06/2013
12	Coinfection 04/2024 - 03/2014
12	Chronic Hepatitis (Chronic Active Hepatitis) 10/2023 - 03/2003
12	Hepatitis C 01/2022 - 03/2003
10	Persistent Infection 12/2023 - 06/2004
10	Disease Progression 01/2023 - 01/2002
10	Viremia 01/2018 - 02/2002
8	Virus Diseases (Viral Diseases) 01/2023 - 09/2003
5	Liver Neoplasms (Liver Cancer) 08/2021 - 10/2016
5	HIV Infections (HIV Infection) 01/2017 - 02/2006
4	Inflammation (Inflammations) 11/2022 - 10/2009
3	Esophageal and Gastric Varices (Esophageal Varices) 01/2023 - 01/2019
3	Portal Hypertension 12/2022 - 03/2011
3	Hypertension (High Blood Pressure) 01/2021 - 01/2018
3	Carcinogenesis 12/2017 - 03/2016
2	Sarcoidosis (Schaumann Disease) 09/2023 - 08/2010
2	Hypercholesterolemia 06/2022 - 07/2009
2	Hemorrhage 01/2022 - 01/2021
2	Asthenia 10/2020 - 01/2013
2	Mitochondrial Diseases (Mitochondrial Disease) 03/2016 - 10/2014
2	Insulin Resistance 03/2016 - 10/2014

Drug/Important Bio-Agent (IBA)

84	Antiviral Agents (Antivirals)IBA 09/2023 - 02/2002
49	Hepatitis B Surface Antigens (HBsAg)FDA Link 04/2024 - 08/2004
36	Hepatitis B e AntigensIBA 10/2023 - 06/2003
33	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 02/2002
27	InterferonsIBA 01/2023 - 01/2002
23	Ribavirin (Virazole)FDA LinkGeneric 10/2020 - 06/2002
21	AntigensIBA 04/2024 - 09/2007
19	NucleosidesIBA 12/2020 - 09/2002
18	Tenofovir (Viread)FDA Link 04/2024 - 07/2009
18	Lamivudine (Epivir)FDA Link 01/2017 - 01/2002
16	RNA (Ribonucleic Acid)IBA 05/2024 - 08/2005
16	entecavir FDA Link 01/2023 - 05/2006
15	Circular DNAIBA 12/2023 - 02/2002
14	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2006
12	VaccinesIBA 01/2021 - 01/2003
11	Interferon-alpha (Interferon Alfa)IBA 01/2020 - 03/2003
10	Biomarkers (Surrogate Marker)IBA 10/2023 - 09/2005
10	Alanine Transaminase (SGPT)IBA 01/2023 - 10/2004
9	NucleotidesIBA 10/2020 - 10/2004
9	Surface Antigens (Surface Antigen)IBA 01/2019 - 08/2004
9	adefovir dipivoxil (Hepsera)FDA Link 10/2010 - 06/2004
7	Protease Inhibitors (Protease Inhibitor)IBA 04/2019 - 12/2011
7	adefovirIBA 03/2017 - 02/2002
7	telaprevirIBA 12/2015 - 11/2012
6	Immunoglobulins (Immunoglobulin)IBA 06/2023 - 10/2006
6	AntibodiesIBA 01/2021 - 01/2010
5	BilirubinIBA 06/2022 - 01/2018
5	Viral DNAIBA 01/2022 - 12/2007
5	CytokinesIBA 12/2019 - 01/2009
5	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 12/2015 - 11/2012
5	RacivirIBA 10/2013 - 09/2002
4	hepatitis B hyperimmune globulinIBA 06/2023 - 10/2006
4	Netrin-1IBA 11/2022 - 03/2016
4	Peptides (Polypeptides)IBA 01/2022 - 01/2012
4	nasIBA 01/2020 - 07/2007
4	SimeprevirIBA 04/2019 - 01/2015
4	LipidsIBA 03/2016 - 02/2009
4	Emtricitabine (Emtriva)FDA Link 04/2014 - 06/2003
3	bulevirtideIBA 01/2023 - 01/2022
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2011
3	JNJ-56136379IBA 01/2023 - 01/2020
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 08/2021 - 01/2021
3	daclatasvirIBA 10/2020 - 11/2016
3	SofosbuvirIBA 10/2020 - 11/2016
3	EnzymesIBA 01/2019 - 01/2017
2	MicroRNAs (MicroRNA)IBA 08/2023 - 01/2009
2	Hepatitis delta Antigens (HDAg)IBA 01/2023 - 04/2015
2	AlbuminsIBA 06/2022 - 01/2022
2	Coffee FDA Link 01/2022 - 01/2019
2	ChromatinIBA 01/2022 - 01/2017
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021 - 01/2009
2	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 01/2021 - 09/2003
2	Immunologic Factors (Immunomodulators)IBA 01/2021 - 09/2003
2	pgRNAIBA 01/2020 - 01/2019
2	Viral RNAIBA 01/2020 - 12/2015
2	Transaminases (Aminotransferases)IBA 01/2019 - 01/2018
2	peginterferon alfa-2a (Pegasys)FDA Link 01/2017 - 01/2015
2	LigandsIBA 03/2016 - 01/2011
2	EpitopesIBA 04/2015 - 11/2010
2	deleobuvirIBA 01/2013 - 12/2011
2	faldaprevirIBA 01/2013 - 12/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2012 - 08/2010
2	DNA VaccinesIBA 03/2012 - 01/2003

Therapy/Procedure

110	Therapeutics 04/2024 - 01/2002
20	Liver Transplantation 06/2023 - 01/2002
5	Transplantation 01/2023 - 01/2018
5	Aftercare (After-Treatment) 06/2022 - 08/2010
4	Duration of Therapy 10/2023 - 01/2015
3	Retreatment 08/2023 - 01/2018
2	Investigational Therapies (Experimental Therapy) 01/2020 - 11/2019